India’s pharmaceutical and Meditech exports have surged, becoming the 4th largest exported goods during the first four months of FY25. Despite the global economic slowdown, the government is optimistic about sustaining this growth, according to Pharma Secretary Arunish Chawla.
Efforts are underway to support the industry in drug development, with 16 blockbuster molecules in the pipeline for production in India. These include treatments targeting cancer, diabetes, and HIV, among others. The manufacturers of these 16 molecules will benefit from incentives under the Production Linked Incentive (PLI) scheme.
Additionally, the government is focusing on enhancing value chains upstream of biological entities, including the production of essential molecules like amino acids, nucleotides, and vaccine raw materials. This strategy is expected to bolster India’s pharmaceutical and biotech sectors further.
